Table 1 Clinico-pathological characteristics of breast cancer patients in the study datasets.
From: A gene expression-based classifier for HER2-low breast cancer
Clinico-pathological characteristics | Discovery set | Confirmatory set | Total n = 304 | |
|---|---|---|---|---|
INT1 | INT2 | INT3 | ||
n = 125 | n = 84 | n = 95 | ||
n (%) | n (%) | n (%) | n (%) | |
Age (years) | ||||
Median (Range) | 49 (26–67) | 53 (26–87) | 60 (35–86) | 52 (26–87) |
Missing | – | 1 | – | 1 |
Tumor size | ||||
≤ 2 cm | 16 (13%) | 1 (1%) | 48 (51%) | 65 (21%) |
2–5 cm | 103 (82%) | 1 (1%) | 42 (44%) | 146 (48%) |
> 5 cm | 5 (4%) | 81 (96%) | 4 (4%) | 90 (30%) |
Missing | 1 (1%) | 1 (1%) | 1 (1%) | 3 (1%) |
Grade | ||||
II | 74 (59%) | 11 (13%) | 46 (48%) | 131 (43%) |
III | 51 (41%) | 73 (87%) | 49 (52%) | 173 (57%) |
Hormone receptors | ||||
Positive | 92 (74%) | 0 (0%) | 78 (82%) | 170 (56%) |
Negative | 30 (24%) | 84 (100%) | 17 (18%) | 131 (43%) |
Missing | 3 (2%) | – | – | 3 (1%) |
HER2 IHC | ||||
0 | 33 (26%) | 52 (62%) | 25 (26%) | 110 (36%) |
1+ | 62 (50%) | 32 (38%) | 26 (27%) | 120 (40%) |
2+ | 12 (10%) | 0 (0%) | 30 (32%) | 42 (14%) |
3+ | 18 (14%) | 0 (0%) | 14 (15%) | 32 (10%) |
PAM50 subtype* | ||||
Luminal A | 41 (33%) | 8 (10%) | 48 (51%) | 97 (32%) |
Luminal B | 23 (18%) | 10 (12%) | 14 (15%) | 47 (16%) |
HER2-enriched | 21 (17%) | 4 (5%) | 12 (13%) | 37 (12%) |
Basal-like | 19 (15%) | 59 (70%) | 15 (16%) | 93 (31%) |
Normal-like | 21 (17%) | 3 (4%) | 0 (0%) | 24 (8%) |
Undetermined | 0 (0%) | 0 (0%) | 6 (6%) | 6 (2%) |
